While there is limited evidence supporting β2-MG as a standalone prognostic marker for pancreatic cancer, its combination with serological markers, such as high preoperative levels of serum tumor markers such as glycan carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and cancer antigen 125 (CA125), is associated with worse tumor differentiation and shorter overall survival. The gene discussed is MUC16; the disease is pancreatic neoplasm.